skip to main content

TKI After ICI irAE RCC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardUrological CancersTKI After ICI irAE RCCSCE Medical Oncology

A patient with metastatic clear-cell RCC progresses after first-line nivolumab-ipilimumab. Treatment also caused grade 3 immune colitis requiring infliximab, and bowel symptoms have now resolved. He has never received a VEGFR tyrosine-kinase inhibitor. Which principle best guides the next systemic-treatment discussion?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Choose a non-checkpoint VEGFR-targeted TKI based on comorbidity, prior toxicity and NHS availability

Progression after nivolumab-ipilimumab does not preclude further RCC therapy. A non-checkpoint VEGFR-targeted TKI can be selected using the current NHS pathway, comorbidity and toxicity profile while avoiding immediate immune rechallenge. Repeating the combination disregards both progression and severe toxicity. Prophylactic infliximab with routine nivolumab rechallenge is not standard. Prior immune colitis does not predict a class-wide recurrence with every VEGFR-targeted TKI, so it does not make everolimus automatically preferable. FOLFOX is not a standard clear-cell RCC regimen and targeted agents are not contraindicated by prior colitis.

Reference: NICE NG256 kidney cancer: managing advanced renal-cell carcinoma (Published March 2026): https://www.nice.org.uk/guidance/NG256/chapter/managing-advanced-renal-cell-carcinoma; CABOMETYX UK summary of product characteristics (Current UK SmPC, accessed July 2026): https://www.medicines.org.uk/emc/product/4331/smpc